Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca reported Q4 2021 financial results, achieving clinical milestones ahead of schedule. The company has a strong cash position of $459 million as of December 31, 2021, up from $118.7 million a year prior. Major trial updates include ERAS-007, ERAS-601, and ERAS-801, with initial Phase 1b data expected in H2 2022. R&D expenses rose to $24.1 million for Q4 2021, reflecting increased clinical trial activity. The net loss improved to $30.5 million for Q4 2021 from $61.9 million in Q4 2020, indicating progress.
Erasca has announced a collaboration with Eli Lilly to evaluate ERAS-007, an ERK1/2 inhibitor, in a Phase 1b/2 HERKULES-3 trial for BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study will explore the combination of ERAS-007 with encorafenib and cetuximab, aiming to overcome resistance mechanisms linked to MAPK pathway reactivation. This approach is bolstered by preclinical data suggesting that ERAS-007 could enhance treatment efficacy. Approximately 180,000 patients with BRAF V600E mutations are affected globally, highlighting the potential market impact.
Erasca, Inc. (Nasdaq: ERAS) announced six poster presentations at the AACR Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The presentations will focus on key product candidates, including ERAS-007, a selective ERK1/2 inhibitor, and ERAS-601, a potent SHP2 inhibitor. Notably, ERAS-601 exhibits strong anti-tumor activity in RAS/MAPK-driven models. Details of the presentations, including dates, times, and locations, are outlined in the announcement. Erasca aims to advance therapies targeting RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. The event, featuring CEO Jonathan E. Lim and CFO David M. Chacko, will take place in a virtual format on February 10, 2022, at 2:30 PM ET. The company will also engage in one-on-one investor meetings. A live webcast will be available at Erasca.com/events, with an archived replay for 30 days afterward. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS) announces key leadership changes with Lisa Tesvich-Bonora appointed as Chief People Officer and Robert Shoemaker promoted to Senior Vice President of Research. Tesvich-Bonora, with over 20 years of experience in organizational development, will lead initiatives in recruitment and professional development. Shoemaker, one of the company’s founding members, will integrate Discovery Research activities to enhance the development of Erasca’s oncology pipeline. These appointments aim to strengthen Erasca's culture and research capabilities.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. During the event, CEO Jonathan E. Lim will present an overview of the company and its pipeline. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the presentation will be accessible online, with an archived replay available for 30 days afterward.
Erasca has achieved FDA clearance for its investigational new drug (IND) application for ERAS-801, an EGFR inhibitor, ahead of schedule. This drug is designed for high CNS penetration to treat recurrent glioblastoma multiforme (rGBM) and will enter the THUNDERBBOLT-1 Phase 1 clinical trial in Q1 2022. The collaboration with the Global Coalition for Adaptive Research (GCAR) aims to explore a path for ERAS-801 within the GBM AGILE trial, enhancing the potential for expedited therapy development. With about 125,000 annual rGBM cases worldwide, this advancement addresses a significant unmet need.
Erasca, Inc. (Nasdaq: ERAS) has been added to the NASDAQ Biotech Index, effective December 20, 2021. This index tracks biotech and pharmaceutical companies listed on the Nasdaq, and membership requires meeting specific criteria, including market capitalization and trading volume. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers and is backed by experts in precision oncology. This inclusion indicates recognition of the company's growth and stability in the biotechnology sector.
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.
Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.
Erasca, Inc. (Nasdaq: ERAS) reported strong execution in its recent financial results for Q3 2021, highlighting the initiation of two clinical trials for ERAS-007 in lung and gastrointestinal cancers. The company maintained a robust cash position of $487 million, bolstered by a $345 million IPO. Notably, it was named one of Fierce Biotech's "Fierce 15" innovative companies. However, the firm reported a net loss of $46.1 million for the quarter, influenced by significant R&D and G&A expenses, including a $17.5 million donation to the Erasca Foundation.